Merck to pay 118% premium to buy cancer drugmaker Harpoon Therapeutics

Merck announced Monday an agreement to buy cancer treatment developer Harpoon Therapeutics in a deal valued at $680 million.

Previous post Oil futures slump as Saudis cut prices
Next post Goldman Sachs sets FTSE 100 target as it says British underperformance will end